Latest Breaking News On - அடித்தளம் மரபியல் - Page 1 : comparemela.com
Why a new breakthrough test for cancer still isn t on the U S market
desmoinesregister.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from desmoinesregister.com Daily Mail and Mail on Sunday newspapers.
Why a new breakthrough test for cancer still isn t on the U S market
usatoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from usatoday.com Daily Mail and Mail on Sunday newspapers.
European Universities Are The Newest Deep Tech Hotspots
forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
ARK Fintech Innovation ETF and the
ARK Next Generation Internet ETF. The digital payment company s share price soared in 2020 after the coronavirus pandemic forced people to rapidly transition from an in-person to an online way of life. Although the stock fell almost 30% from its all-time high during the February tech sell-off, it now seems to be on a path of recovery.
The digital payments market was estimated to be worth $58.3 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2021 to 2028. Considering the huge opportunity unfolding, PayPal s offerings in areas such as peer-to-peer payments, cashless payments for online and offline purchases, and credit have been in huge demand. In fact, the company recorded 72.7 million new accounts and reached a total of 377 million in 2020, and total payment volume (TPV) jumped by 31% year over year to $936 billion. PayPal aims to increase active accounts to 750 million and TPV to $2.8 trillion by 202
SHELLEY K. MESCH
When Exact Sciences moved to Madison from Boston in 2009, the company had 20 employees and the intention of developing a colon cancer screening test.
Now, millions of people are screened each year using Exact Sciencesâ Cologuard, the company employs more than 5,000 people, and multiple tests are in development for various types and aspects of cancer.
In the last three years, Exact Sciences has broadened its diagnostic abilities by acquiring several companies and purchasing the exclusive use of a testing technology that can detect cancer. The acquired products, both in commercial use and in development, range from screening for cancer, determining the best course of treatment for a cancer patient, and testing blood for recurring cancer.